New insights into the antimicrobial effect of mast cells against Enterococcus faecalis

Infection and Immunity

Volumn 82, Issue 11, 2014, Pages 4496-4507

  Scheb Wetzel, Matthias ^a   Rohde, Manfred ^a   Bravo, Alicia ^b   Goldmann, Oliver ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BONE MARROW DERIVED MAST CELL; CELL POPULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOUBLE IMMUNOFLUORESCENCE MICROSCOPY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; GENE EXPRESSION; GROWTH INHIBITION; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATORY CELL; INNATE IMMUNITY; INTERNALIZATION; LAMINA PROPRIA; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PATTERN RECOGNITION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ANIMAL; BACTERIUM ADHERENCE; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; GENETICS; GERMFREE ANIMAL; GRAM POSITIVE INFECTION; IMMUNOLOGY; KNOCKOUT MOUSE; MAST CELL; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; BACTERIAL ADHESION; BONE MARROW CELLS; CELLS, CULTURED; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TOLL-LIKE RECEPTOR 2;

EID: 84907958784     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02114-14     Document Type: Article

References (53)

1. Fisher K, Phillips C. 2009. The ecology, epidemiology and virulence of Enterococcus. Microbiology 155:1749-1757. http://dx.doi.org/10.1099/mic.0.026385-0.
2. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat. Rev. Microbiol. 10:266-278. http://dx.doi.org/10.1038/nrmicro2761.
3. Schmidt-Hieber M, Blau IW, Schwartz S, Uharek L, Weist K, Eckmanns T, Jonas D, Ruden H, Thiel E, Brandt C. 2007. Intensified strategies to control vancomycin-resistant enterococci in immunocompromised patients. Int. J. Hematol. 86:158-162. http://dx.doi.org/10.1532/IJH97.E0632.
4. Hollenbeck BL, Rice LB. 2012. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 3:421-433. http://dx.doi.org/10.4161/viru.21282.
5. Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A. 2010. Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium. Clin. Microbiol. Infect. 16:541-554. http://dx.doi.org/10.1111/j.1469-0691.2010.03226.x.
6. Arias CA, Murray BE. 2008. Emergence and management of drugresistant enterococcal infections. Expert Rev. Anti Infect. Ther. 6:637-655. http://dx.doi.org/10.1586/14787210.6.5.637.
7. Wallace JL, Granger DN. 1996. The cellular and molecular basis of gastric mucosal defense. FASEB J. 10:731-740.
8. Wallace JL, Ma L. 2001. Inflammatory mediators in gastrointestinal defense and injury. Exp. Biol. Med. 226:1003-1015. http://dx.doi.org/10.3181/00379727-214-44087.
9. Wasserman SI, Marquardt DL, Broide D, Walker L, Barrett K. 1989. Characterization, activation, and functional importance of mucosal mast cells. Prog. Clin. Biol. Res. 297:155-161; discussion, 161.
10. Dawicki W, Marshall JS. 2007. New and emerging roles for mast cells in host defence. Curr. Opin. Immunol. 19:31-38. http://dx.doi.org/10.1016/j.coi.2006.11.006.
11. Marshall JS. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4:787-799. http://dx.doi.org/10.1038/nri1460.
12. Yang Z, Marshall JS. 2009. Zymosan treatment of mouse mast cells enhances dectin-1 expression and induces dectin-1-dependent reactive oxygen species (ROS) generation. Immunobiology 214:321-330. http://dx.doi.org/10.1016/j.imbio.2008.09.002.
13. Bischoff SC. 2007. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat. Rev. Immunol. 7:93-104. http://dx.doi.org/10.1038/nri2018.
14. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F. 2003. Mast cells in allergy and beyond. Int. J. Biochem. Cell Biol. 35:1601-1607. http://dx.doi.org/10.1016/S1357-2725(03)00208-5.
15. Urb M, Sheppard DC. 2012. The role of mast cells in the defence against pathogens. PLoS Pathog. 8:e1002619. http://dx.doi.org/10.1371/journal.ppat.1002619.
16. Féger F, Varadaradjalou S, Gao Z, Abraham SN, Arock M. 2002. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol. 23:151-158. http://dx.doi.org/10.1016/S1471-4906(01)02156-1.
17. von Köckritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norrby-Teglund A, Rohde M, Medina E. 2008. Phagocytosisindependent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 111:3070-3080. http://dx.doi.org/10.1182/blood-2007-07-104018.
18. Abel J, Goldmann O, Ziegler C, Holtje C, Smeltzer MS, Cheung AL, Bruhn D, Rohde M, Medina E. 2011. Staphylococcus aureus evades the extracellular antimicrobial activity of mast cells by promoting its own uptake. J. Innate Immun. 3:495-507. http://dx.doi.org/10.1159/000327714.
19. Kuehn HS, Radinger M, Gilfillan AM. 2010. Measuring mast cell mediator release. Curr. Protoc. Immunol. 91:7.38.1-7.38.9. http://dx.doi.org/10.1002/0471142735.im0738s91.
20. Di Nardo A, Vitiello A, Gallo RL. 2003. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170:2274-2278. http://dx.doi.org/10.4049/jimmunol.170.5.2274.
21. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. 2014. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J. Invest. Dermatol. http://dx.doi.org/10.1038/jid.2014.222.
22. Karchmer AW. 2000. Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin. Infect. Dis. 31(Suppl 4):S139-S143. http://dx.doi.org/10.1086/314078.
23. Dupont H. 2007. The empiric treatment of nosocomial intra-abdominal infections. Int. J. Infect. Dis. 11(Suppl 1):S1-S6. http://dx.doi.org/10.1016/S1201-9712(07)60001-0.
24. Rybak JM, Barber KE, Rybak MJ. 2013. Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin. Pharmacother. 14:1919-1932. http://dx.doi.org/10.1517/14656566.2013.820276.
25. Werner G, Coque TM, Franz CM, Grohmann E, Hegstad K, Jensen L, van Schaik W, Weaver K. 2013. Antibiotic resistant enterococci-tales of a drug resistance gene trafficker. Int. J. Med. Microbiol. 303:360-379. http://dx.doi.org/10.1016/j.ijmm.2013.03.001.
26. Kayaoglu G, Orstavik D. 2004. Virulence factors of Enterococcus faecalis: relationship to endodontic disease. Crit. Rev. Oral Biol. Med. 15:308-320. http://dx.doi.org/10.1177/154411130401500506.
27. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011. http://dx.doi.org/10.1086/591861.
28. Rice LB. 2001. Emergence of vancomycin-resistant enterococci. Emerg. Infect. Dis. 7:183-187. http://dx.doi.org/10.3201/eid0702.010205.
29. Arduino RC, Murray BE, Rakita RM. 1994. Roles of antibodies and complement in phagocytic killing of enterococci. Infect. Immun. 62:987-993.
30. Abraham SN, Malaviya R. 1997. Mast cells in infection and immunity. Infect. Immun. 65:3501-3508.
31. Shelburne CP, McLachlan JB, Abraham SN. 2006. In vivo models for studying mast cell-dependent responses to bacterial infection. Methods Mol. Biol. 315:363-381.
32. Shin JS, Gao Z, Abraham SN. 2000. Involvement of cellular caveolae in bacterial entry into mast cells. Science 289:785-788. http://dx.doi.org/10.1126/science.289.5480.785.
33. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. 2007. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176:231-241. http://dx.doi.org/10.1083/jcb.200606027.
34. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SN. 1998. Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect. Immun. 66:6030-6034.
35. Schechter NM, Wang ZM, Blacher RW, Lessin SR, Lazarus GS, Rubin H. 1994. Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions. J. Immunol. 152:4062-4069.
36. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347:1151-1160. http://dx.doi.org/10.1056/NEJMoa021481.
37. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB, Jr, Lehrer RI, Welsh MJ, Tack BF. 2000. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect. Immun. 68:2748-2755. http://dx.doi.org/10.1128/IAI.68.5.2748-2755.2000.
38. Bals R, Wang X, Zasloff M, Wilson JM. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. U. S. A. 95:9541-9546. http://dx.doi.org/10.1073/pnas.95.16.9541.
39. Yan H, Hancock RE. 2001. Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob. Agents Chemother. 45:1558-1560. http://dx.doi.org/10.1128/AAC.45.5.1558-1560.2001.
40. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. 2002. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 46:157-168. http://dx.doi.org/10.1046/j.1365-2958.2002.03146.x.
41. Leszczynska K, Namiot D, Byfield FJ, Cruz K, Zendzian-Piotrowska M, Fein DE, Savage PB, Diamond S, McCulloch CA, Janmey PA, Bucki R. 2013. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J. Antimicrob. Chemother. 68:610-618. http://dx.doi.org/10.1093/jac/dks434.
42. d'Enfert C, Reyss I, Wandersman C, Pugsley AP. 1989. Protein secretion by gram-negative bacteria. Characterization of two membrane proteins required for pullulanase secretion by Escherichia coli K-12. J. Biol. Chem. 264:17462-17468.
43. Guidi R, Levi L, Rouf SF, Puiac S, Rhen M, Frisan T. 2013. Salmonella enterica delivers its genotoxin through outer membrane vesicles secreted from infected cells. Cell. Microbiol. 15:2034-2050. http://dx.doi.org/10.1111/cmi.12172.
44. Macdonald IA, Kuehn MJ. 2013. Stress-induced outer membrane vesicle production by Pseudomonas aeruginosa. J. Bacteriol. 195:2971-2981. http://dx.doi.org/10.1128/JB.02267-12.
45. Matias VR, Beveridge TJ. 2006. Native cell wall organization shown by cryo-electron microscopy confirms the existence of a periplasmic space in Staphylococcus aureus. J. Bacteriol. 188:1011-1021. http://dx.doi.org/10.1128/JB.188.3.1011-1021.2006.
46. Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, Kim SH, Desiderio DM, Kim YK, Kim KP, Gho YS. 2009. Gram-positive bacteria produce membrane vesicles: proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles. Proteomics 9:5425-5436. http://dx.doi.org/10.1002/pmic.200900338.
47. Olaya-Abril A, Prados-Rosales R, McConnell MJ, Martin-Pena R, Gonzalez-Reyes JA, Jimenez-Munguia I, Gomez-Gascon L, Fernandez J, Luque-Garcia JL, Garcia-Lidon C, Estevez H, Pachon J, Obando I, Casadevall A, Pirofski LA, Rodriguez-Ortega MJ. 2014. Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. J. Proteomics 106:46-60. http://dx.doi.org/10.1016/j.jprot.2014.04.023.
48. Prados-Rosales R, Baena A, Martinez LR, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, Camara C, Nosanchuk JD, Besra GS, Chen B, Jimenez J, Glatman-Freedman A, Jacobs WR, Jr, Porcelli SA, Casadevall A. 2011. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J. Clin. Invest. 121:1471-1483. http://dx.doi.org/10.1172/JCI44261.
49. Rivera J, Cordero RJ, Nakouzi AS, Frases S, Nicola A, Casadevall A. 2010. Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc. Natl. Acad. Sci. U. S. A. 107:19002-19007. http://dx.doi.org/10.1073/pnas.1008843107.
50. Rodriguez AR, Yu JJ, Guentzel MN, Navara CS, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. 2012. Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis. J. Immunol. 188:5604-5611. http://dx.doi.org/10.4049/jimmunol.1200039.
51. Park OJ, Han JY, Baik JE, Jeon JH, Kang SS, Yun CH, Oh JW, Seo HS, Han SH. 2013. Lipoteichoic acid of Enterococcus faecalis induces the expression of chemokines via TLR2 and PAFR signaling pathways. J. Leukoc. Biol. 94:1275-1284. http://dx.doi.org/10.1189/jlb.1012522.
52. Inoue R, Nagino T, Hoshino G, Ushida K. 2011. Nucleic acids of Enterococcus faecalis strain EC-12 are potent Toll-like receptor 7 and 9 ligands inducing interleukin-12 production from murine splenocytes and murine macrophage cell line J774.1. FEMS Immunol. Med. Microbiol. 61:94-102. http://dx.doi.org/10.1111/j.1574-695X.2010.00752.x.
53. Dawicki W, Jawdat DW, Xu N, Marshall JS. 2010. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J. Immunol. 184:2116-2123. http://dx.doi.org/10.4049/jimmunol.0803894.